Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818986 · ClinicalTrials.gov registry record · Phase 2
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01818986 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT01818986, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergistically to the concurrently administered immunotherapy Sipuleucel-T and thereby significantly improve the treatment outcome for metastatic castrate resistant prostate cancer patients (mCRPC). Both Sipuleucel-T and SABR are FDA approved therapeutic cancer treatment
Interventions
- DRUG Sipuleucel-T
- RADIATION Stereotactic Ablative Body Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-07-10 |
| Est. Completion | 2021-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01818986
The ClinicalTrials.gov registry entry for NCT01818986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sipuleucel-T is the first listed.
NCT01818986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01818986 about?
NCT01818986 is a clinical study titled "Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)". In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergi...
What is the current status of trial NCT01818986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-07-10. Estimated completion is 2021-05-25.
What interventions are being tested in trial NCT01818986?
The interventions under investigation include: Sipuleucel-T (DRUG), Stereotactic Ablative Body Radiation (RADIATION).
Who is sponsoring clinical trial NCT01818986?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.